4D Molecular Therapeutics, Inc. cotiza a 13.00 USD y tiene una capitalización bursátil de $718M. En los últimos 12 meses ha facturado $92M con un margen de flujo de caja libre del -128.7%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatm…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | $-1.04 | — | $-1.01 |
| Estimado | $-1.05 | $-1.02 | $-1.02 | $-1.00 |
| Sorpresa | — | -2.0% | — | -1.0% |
| Métrica | FDMT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -187.2% | -38.6% | -148.6% |
| Net Margin | -164.4% | -33.6% | -130.9% |
| FCF Margin | -128.7% | -13.9% | -114.8% |
| ROE | -27.7% | -40.4% | +12.7% |
| ROA | -24.7% | -32.0% | +7.3% |
| Current Ratio | 9.39 | 2.84 | +6.55 |
| Debt / Equity | — | 0.28 | — |